Clinical trials: Cirrhosis, Liver
Decompensated Cirrhosis, Liver Transplantation
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation
The MELD score is a predictive model of cirrhosis mortality used in France since 2007 to prioritize access to liver transplantation for patients enrolled in the national waiting list.
- Trial name
- SUPERMELD (NCT03820271)
- Testing
- SuperMELD
- Where
- France
- Volunteers
- 501 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Hepatorenal Syndrome, Liver Cirrhosis
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
- Conditions
- Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
- Trial name
- NCT06256432
- Testing
- Ambrisentan, Terlipressin
- Where
- 6 sites in India
- Volunteers
- 54 people
- Sponsor
- Noorik Biopharmaceuticals AG
Esophageal Varices Bleeding
The Compliance and Prognosis of NSBB Secondary Prevention of Cirrhosis With Gastroesophageal Varices Bleeding
Non-selective beta blockers are commonly used drugs for primary prevention and secondary prevention in patients with cirrhotic decompensated esophageal varices bleeding，the basic heart rate, blood pressure and condition of…
- Trial name
- NCT03683121
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Renmin Hospital of Wuhan University
Hepatitis C, Chronic, Liver Cirrhosis
Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and type C compensated cirrhosis.
- Trial name
- NCT00811967
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cirrhosis
Anticoagulation for Advanced Cirrhotic Patients After TIPS
Recent studies demonstrated that liver cirrhosis was associated with a hypercoagulability state. Besides, bacterial translocation plays an important role in the pathogenesis and complications in patients with decompensated…
- Trial name
- NCT03005444
- Testing
- Rivaroxaban
- Where
- 11 sites in China
- Volunteers
- 254 people
- Sponsor
- Air Force Military Medical University, China
Liver Cirrhosis
Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE).
- Trial name
- PYROCALM (NCT07201649)
- Testing
- a blood test and urine sample collection.
- Where
- France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Advanced Cirrhosis
Efficacy and Safety of Endoscopic Variceal Ligation (EVL) Versus EVL Plus Non-selective B-blockers (NSBB) For Prevention of Variceal Rebleed and Non-bleed Related Complications in Patients With Advanced Cirrhosis
The patients will be randomized into two groups 1. Endoscopic Variceal Ligation with Non Selective Beta Blocker 2. Placebo with Endoscopic Variceal Ligation
- Trial name
- NCT02739581
- Testing
- Endoscopic Variceal Ligation, Non selective beta blocker
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting treatments on driving risks.
- Trial name
- AutoSop-Foie (NCT01231828)
- Testing
- L-carnitine, Lactulose
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Caen
Primary Biliary Cholangitis
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
This study will collect information from patients with Primary Biliary Cholangitis (PBC). PBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged.
- Trial name
- NCT07049887
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ipsen
Hepatitis, Liver Cirrhosis
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding…
- Conditions
- Hepatitis, Liver Cirrhosis, Hepatocellular Carcinoma
- Trial name
- NCT00679692
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Hepatic Cirrhosis, Alcoholism
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
The purpose of this study is to evaluate the effect of varying degrees of hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of pasireotide s.c. in subjects.
- Trial name
- NCT00698464
- Testing
- Pasireotide
- Where
- 4 sites in United States, Belgium and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Liver Fibrosis
Development of a Novel Biomarker for Liver Fibrosis
The overall aim of this study is to validate a quantitative digital tool for staging liver fibrosis in biopsies from chronic human liver diseases and then evaluate it prospectively in patients.
- Trial name
- NCT02348814
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Primary Biliary Cholangitis
EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study
A prospective, single centre, single-arm, pilot study investigating the safety and efficacy of a 12-week remotely-monitored home-based exercise program in patients with refractory fatigue (based on PBC-40 Quality of Life measure)…
- Trial name
- EXCITED (NCT04265235)
- Testing
- Home-based exercise program
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Birmingham
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Hyponatremia
Study of Ascending Levels of Tolvaptan in Hyponatremia
The purpose of this study was to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this…
- Trial name
- SALT2 (NCT00201994)
- Testing
- Tolvaptan
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcoholic Cirrhosis, Alcoholic Liver Disease
Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
Investigator seek to determine whether the volume of the liver can predict the survival after a decompensation of a patient suffering from chronic liver disease caused by excessive alcohol consumption (or alcoholic cirrhosis).
- Trial name
- PROLIV (NCT03508388)
- Where
- France
- Volunteers
- 142 people
- Sponsor
- University Hospital, Montpellier
Alcoholic Hepatitis, Alcoholic Cirrhosis
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
The purpose of this study is to validate a strategy of identification of patients for early liver transplantation in severe alcoholic hepatitis. In this setting, short-term survival is very low (approx.
- Trial name
- QuickTrans (NCT01756794)
- Testing
- Liver transplantation
- Where
- 32 sites in Belgium, France
- Volunteers
- 284 people
- Sponsor
- University Hospital, Lille
Cirrhosis, Liver, Advanced Liver Fibrosis
Erlotinib for Hepatocellular Carcinoma Chemoprevention
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
- Trial name
- ECHO-B (NCT04172779)
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.